About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

NCT01026415·6 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Seagen Inc.

With

Millennium Pharmaceuticals, Inc.

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Adequate organ function (Special Populations: serum bilirubin \>2 mg/dL or creatinine clearance \<50 mL/min)
ECOG performance status \<2 (Special Populations: \<4)
Relapsed or refractory CD30-positive malignancy

You may not be if

Receiving prohibited medication within 4 weeks
Poor liver function (Child-Pugh class C)
Current diagnosis of primary cutaneous ALCL
Acute or chronic graft-versus-host disease

The record

StatusCompleted

PhasePhase 1

Taking part73

StartedDec 2009

UpdatedDec 18, 2014

Conditions

Carcinomas Disease, Hodgkin Lymphoma, Large-Cell, Anaplastic Lymphoma, Non-Hodgkin Neoplasms

Where6

City of Hope
Duarte, California, United States
Colorado Blood Cancer Institute
Denver, Colorado, United States
St. Francis Medical Group Oncology & Hematology Specialists
Indianapolis, Indiana, United States